Amprenavir: all 21 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive AdultsTerminatedNCT02182765Phase 1
- Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure.CompletedNCT00196625Phase 2
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected PatientsCompletedNCT00056641Phase 2
- Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAARTCompletedNCT00038532Phase 2
- Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease InhibitorCompletedNCT00038519Phase 2/3
- Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected PatientsCompletedNCT00006617Not applicable
- Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative VolunteersCompletedNCT00005762Not applicable
- A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include AmprenavirCompletedNCT00002423Phase 2
- Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor TreatmentCompletedNCT00002419Phase 2
- A Study of Amprenavir in Patients With Protease Inhibitor-Related ComplicationsCompletedNCT00002417Not applicable
- A Study of Amprenavir in HIV-Infected PatientsCompletedNCT00002405Not applicable
- A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected PatientsCompletedNCT00002245Phase 3
- A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected AdultsCompletedNCT00002239Phase 2
- A Study of a Combination of Four Drugs in Patients With Recent HIV InfectionCompletedNCT00002233Phase 2
- An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment RegimenCompletedNCT00002205Not applicable
- Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease InhibitorsCompletedNCT00002193Phase 3
- Once-Daily Drug Regimen for HIV-Infected PatientsCompletedNCT00001968Phase 1
- Continued Antiretroviral Therapy With Abacavir, Amprenavir and EfavirenzCompletedNCT00001758Phase 2
- A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken AmprenavirCompletedNCT00001095Phase 2
- Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIVCompletedNCT00000940Phase 2
- A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive PatientsCompletedNCT00000912Phase 2